Skip to content
thispeptide

Signos

Signos+ combines compounded GLP-1 access with glucose monitoring and an app. OpenLoop handles clinical care; the device, coaching and medication each need to be understood on their own terms.

Review by Leah Garner, clinical-evidence editor · Updated October 2026

The short version

The combination may interest someone who wants structured behavior tracking alongside prescribing. A glucose trace does not establish medication effectiveness, and the prescribing relationship remains with an independent clinical group.

Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

Signos, Inc. operates a glucose-monitoring platform and wellness program. Its separate Signos+ offer adds compounded semaglutide or tirzepatide through independent clinicians. The general CGM membership and the pharmaceutical subscription have distinct services and policies. A device-centered homepage therefore does not explain every condition of the medicine program.

What Signos prescribes, by goal

Weight

  • SemaglutideFDA-approved

    Listed by the seller; no price we hold.

    • TirzepatideFDA-approved

      Listed by the seller; no price we hold.

      The program identifies compounded semaglutide and tirzepatide. It combines prescribing with CGM data, meal guidance, activity tracking and app-based feedback. The medication route and individual directions should be confirmed rather than inferred from the device bundle. Sensor feedback should not be used to change a prescribed dose without clinical advice.

      Who prescribes

      A licensed clinician

      The medical network is provided through OpenLoop and other independent U.S. clinicians. Signos does not itself practice medicine or control prescribing decisions. The terms name potential pharmacy partners including RedRock, Health Warehouse, Precision Medicine and Triad Rx. Confirm the assigned clinician and actual dispensing facility; neither is established by joining the platform alone.

      The Signos+ page describes a medical intake followed by clinician-guided treatment and program support. It says a video visit is needed in several listed jurisdictions. Its eligibility answer excludes Louisiana, while the broader legal text refers to all fifty states and Washington, DC with service limitations. Ask which statement applies to the selected preparation and current location before paying.

      Are labs required?

      Not mentioned

      The legal agreement says services, laboratory work and medication included within a pharmaceutical subscription may vary. A continuous glucose sensor is not a universal replacement for laboratory tests or clinical evaluation. Ask what additional testing the prescriber requires, who interprets it and whether a separate bill can arise.

      Ready to start with Signos?

      Prices and plans are set on the seller's own site.

      What it claims, and what it cites

      Signos labels several charts as illustrative and describes testimonials as individual experiences. Its glucose-monitoring clearance concerns the device’s specified function, not FDA approval of the compounded medication. A projected weight-loss curve does not establish a personal outcome. Ask what the actual clinical plan changes in response to monitoring, rather than assuming more data automatically produces better treatment.

      How it bills

      The Signos+ starting figure is attached to a three- or six-month program, not a verified standalone month for a specified prescription. Pharmaceutical cancellation requires at least seventy-two hours before billing. Clinical disqualification has specific refund provisions; ordinary cancellation generally does not. Read those rules separately from any glucose-monitoring-only guarantee.

      For and against

      • For: Independent clinical group identified
      • For: Potential pharmacies named
      • For: Device and medication roles distinguished
      • For: Illustrative charts carry qualifications
      • Against: Actual preparation needs confirmation
      • Against: Geographic descriptions conflict
      • Against: Included tests vary by service
      • Against: Pharmaceutical refunds differ from general program claims

      The evidence behind what it sells

      Right for

      Someone seeking coordinated glucose tracking and medical access who will clarify the actual clinical decisions and commitment.

      Look elsewhere if

      Someone treating device clearance, an app prediction or an illustrative chart as proof a compounded treatment will work.

      Other sellers for weight

      Signos

      Frequently asked questions

      Does the glucose monitor’s clearance approve the medication?
      No. Device clearance concerns the monitoring system; compounded semaglutide and tirzepatide are not FDA-approved.
      Is Signos+ available in every state?
      The program page excludes Louisiana, while general legal language is broader. Confirm current eligibility for the specific prescription and location.

      Sources

      • CGM-centered platform and independent clinical-service disclaimer
      • Active Signos+ compounded GLP-1 program, commitment and geographic exceptions
      • Pharmaceutical subscription cancellation, medical disqualification and pharmacy partners

      See what Signos prescribes today

      Signos sets its own prices, plans and the states it serves. Check them before you start.

      Written by Leah Garner from Signos’s own public pages, against the published methodology. No outcome is claimed first-hand and no score is given. A partnership never changes what this page says; see how the site is paid.